The compensatory upregulation of molecular target structures, such as EGFR or IGF1R, for example, leads to reduced sensitivity to erlotinib (EGFR inhibitor) or substances targeting the VEGF signaling pathway (IGF1R contributes to tumor angiogenesis through upregulation of VEGF) [302,303,304]. The gene discussed is IGF1R; the disease is neoplasm.